Shared Psychiatric Risk and Your Genetics

By the ExomeDNA Science Team | This page contains general information only. For personal health decisions, consult a qualified clinician.

Shared psychiatric risk describes a cluster of genetic variants that simultaneously increase predisposition to schizophrenia, bipolar disorder, and major depressive disorder — three conditions that, despite their distinct clinical presentations, share a substantial overlapping genomic foundation. A landmark 2022 sex-stratified genome-wide analysis (Blokland et al., PMID 34099189) identified cross-diagnostic loci operating through at least three distinct biological pathways: complement-mediated synaptic pruning (CSMD3), neurotrophic and axon-guidance factor maturation (PCSK5), and blood-brain barrier permeability (PECAM1). Below: the science behind each pathway, what the evidence shows, and practical considerations for working with your result.

What is shared psychiatric risk?

Shared psychiatric risk refers to the proportion of genetic liability that is held in common across schizophrenia (SCZ), bipolar disorder (BPD), and major depressive disorder (MDD). Psychiatric genetics research has consistently shown that these three conditions are not genetically independent. Studies using genome-wide association data estimate genetic correlations of approximately 0.68 between SCZ and BPD, 0.45 between BPD and MDD, and 0.34 between SCZ and MDD — figures that reflect real shared molecular mechanisms rather than diagnostic imprecision.

A transdiagnostic result on this trait reflects variants at loci where a single allele shifts risk modestly upward or downward across all three conditions simultaneously. This page covers the three authorized loci — CSMD3, PCSK5, and PECAM1 — each contributing through a biologically distinct mechanism. The trait does not indicate that any specific condition will develop. It describes genetic context that overlaps the liability architecture of all three.

The category for this trait is Brain and Mental Health. Sensitive framing is appropriate throughout: psychiatric conditions are common, heterogeneous, and strongly shaped by non-genetic factors including environment, early life stress, sleep, inflammation, and social determinants of health. Genetic predisposition is one input among many.

The genetics behind shared psychiatric risk

Three genes anchor this trait's biological story, each mechanistically distinct.

CSMD3 — complement regulation and synaptic pruning. CSMD3 (CUB and sushi multiple domains 3) is one of the largest protein-coding genes in the human genome, spanning approximately three megabases on chromosome 8. It encodes a massive extracellular scaffold carrying multiple CUB and sushi/SCR domains — structural motifs found throughout the complement pathway. CSMD3 is expressed in neurons and glia throughout developing and adult brain and belongs to the CSMD family (CSMD1, CSMD2, CSMD3) of complement regulatory proteins in the central nervous system.

The mechanism connects to the complement-synaptic pruning hypothesis of schizophrenia, one of the most actively investigated frameworks in contemporary psychiatric genetics. During normal adolescent brain development, complement proteins C1q and C4A tag weak or redundant synapses for elimination by microglia — a process essential for circuit refinement. CUB and sushi domain proteins like CSMD3 regulate the activity of complement at synaptic surfaces; reduced CSMD3 function may allow excessive complement-mediated synapse elimination, producing over-pruned circuits with reduced synaptic density. Reduced dendritic spine density is documented post-mortem in schizophrenia, bipolar disorder, and major depressive disorder, connecting this pruning mechanism to all three conditions. CSMD3 appears across GWAS for all three conditions, making it a genuine transdiagnostic signal rather than a disorder-specific one.

PCSK5 — BDNF and netrin-1 maturation. PCSK5 (proprotein convertase subtilisin/kexin type 5) is a serine protease that cleaves precursor proteins at paired basic amino acid sites. Two substrates are particularly relevant to cross-diagnostic psychiatric risk.

First, PCSK5 cleaves proBDNF to yield mature brain-derived neurotrophic factor. Mature BDNF binds TrkB receptors to promote neuronal survival and synaptic plasticity; the precursor form, proBDNF, instead activates p75NTR receptors and favors apoptotic signaling. The ratio of mature BDNF to proBDNF at synapses therefore determines whether neurotrophic signaling promotes survival or pruning. PCSK5 variants that reduce cleavage efficiency shift this ratio toward proBDNF, a perturbation linked to both reduced hippocampal volume and impaired prefrontal connectivity — phenotypes observed across schizophrenia, bipolar disorder, and depression.

Second, PCSK5 processes netrin-1 precursor. Netrin-1, a laminin-related axon guidance cue, steers mesocortical dopamine axons from the ventral midbrain to the prefrontal cortex. Disrupted netrin-1 maturation compromises the dopamine projections whose dysregulation is a core feature of schizophrenia and bipolar disorder. Because PCSK5 simultaneously affects neurotrophic support (relevant to depression) and dopamine circuit guidance (relevant to psychosis and mania), its transdiagnostic association reflects a genuine convergence of two critical pathways in a single enzyme.

PECAM1 — blood-brain barrier integrity and neuroinflammation. PECAM1 (platelet and endothelial cell adhesion molecule 1, also known as CD31) is expressed at endothelial cell junctions, on platelets, and on leukocytes. At the blood-brain barrier, PECAM1 governs leukocyte transmigration — the controlled passage of immune cells from peripheral blood into brain tissue.

Variants affecting PECAM1 function alter BBB permeability. A more permeable BBB allows peripheral inflammatory cytokines (including IL-6, TNF-alpha, and IL-1beta) to enter the CNS, and enables activated monocytes and T cells to infiltrate brain parenchyma and trigger neuroinflammatory cascades. Elevated neuroinflammatory markers — raised CSF cytokines, activated microglia on PET imaging, elevated CRP in peripheral blood — are documented across schizophrenia, bipolar disorder, and major depressive disorder. The shared neuroinflammatory component is increasingly recognized as a transdiagnostic pathophysiological mechanism rather than an epiphenomenon.

What the research says

Research base: Robust.

The authorized primary source is Blokland GAM et al. (2022), PMID 34099189, a sex-stratified genome-wide association study of mood and psychotic disorder cross-diagnostic phenotypes. The study examined genetic architecture shared and not shared between sexes across these conditions, identifying loci with cross-diagnostic effects operating through the complement, neurotrophic, and vascular mechanisms described above.

Key quantitative context:

• Genetic correlation estimates between SCZ and BPD reach approximately 0.68 in large cross-disorder analyses, the highest pairwise figure in the psychiatric genetics literature.
• Genetic correlation between BPD and MDD is approximately 0.45; between SCZ and MDD approximately 0.34 — all substantial, all indicating shared genomic architecture.
• The complement-synaptic pruning pathway: C4A gene copy number is among the most replicated schizophrenia risk modulators, and the CSMD family's regulatory role in this cascade has been supported across independent cohorts.
• BDNF serum levels are reduced approximately 20-30% in large meta-analyses of depression and bipolar disorder relative to controls, consistent with the PCSK5-BDNF maturation mechanism.
• Blood-brain barrier disruption, indexed by albumin CSF/plasma ratios, is elevated in a subset of individuals across all three diagnostic categories, supporting the PECAM1 pathway as transdiagnostically relevant.

Cross-disorder psychiatric genomics is a rapidly evolving field. Findings represent population-level associations; individual-level predictions from any single locus remain modest.

How shared psychiatric risk affects you

The transdiagnostic framing of this trait has several practical implications for understanding the result.

A higher-polygenic result on this trait does not indicate that any condition is inevitable or even likely in isolation. The three conditions covered by this trait each have complex, multifactorial etiologies. Heritability estimates for schizophrenia (~80%), bipolar disorder (~70-80%), and major depressive disorder (~35-40%) reflect the contribution of thousands of variants across the genome; this trait captures one slice of that architecture.

The three mechanisms highlighted — complement-mediated pruning, neurotrophic factor maturation, and blood-brain barrier integrity — are all modifiable through lifestyle and environmental factors to varying degrees:

• CSMD3 / synaptic pruning: The complement-mediated pruning cascade is modulated by sleep. Chronic sleep deprivation is associated with upregulated complement activity in the brain. Consistent sleep duration and quality is a direct lever on the pruning mechanism this gene participates in.

• PCSK5 / BDNF pathway: Aerobic exercise is among the most robust known upregulators of BDNF expression and maturation. Multiple meta-analyses confirm that sustained aerobic activity — 150+ minutes per week at moderate intensity — raises peripheral BDNF levels and is associated with increased hippocampal volume over time.

• PECAM1 / blood-brain barrier: BBB integrity is compromised by systemic inflammation (elevated CRP, obesity, metabolic syndrome), chronic psychological stress, and alcohol. Anti-inflammatory dietary patterns, weight management, stress reduction practices, and alcohol moderation all reduce peripheral inflammation that crosses or compromises the barrier.

These are not condition-specific recommendations; they are foundational lifestyle factors that act directly on the three biological mechanisms the associated genes participate in.

Working with your shared psychiatric risk result

A higher result on this trait is worth discussing with a clinician, particularly for those with a personal or family history of any of the three covered conditions. A numbered list of practical steps follows:

1. Share the result with your clinician at your next visit. This provides context for psychiatric history conversations and may inform monitoring, particularly around major life transitions associated with first-episode onset (late adolescence, early adulthood, postpartum period).
2. Prioritize sleep hygiene. Target 7-9 hours of consistent sleep. The complement-pruning mechanism this trait involves is directly modulated by sleep-wake cycles; chronic disruption increases microglial activation.
3. Establish a consistent aerobic exercise routine. A minimum of 150 minutes per week of moderate-intensity aerobic activity is supported by meta-analytic evidence for BDNF upregulation. This directly engages the PCSK5-BDNF maturation pathway.
4. Reduce systemic inflammatory load. An anti-inflammatory dietary pattern, weight in the healthy range, and alcohol moderation all reduce peripheral cytokine levels relevant to blood-brain barrier integrity.
5. Monitor stress exposure and build recovery practices. Chronic psychological stress drives HPA axis activation and peripheral inflammation, both of which compound genetic risk through the neuroinflammatory pathway.
6. Know early signs across all three conditions. Because this is a transdiagnostic trait, awareness spans mood episodes (BPD, MDD) and perceptual or cognitive changes (SCZ). Early intervention is consistently associated with better long-term outcomes across all three.

This section is informational. It does not constitute personalized health guidance. A qualified clinician is the appropriate person to interpret genetic context alongside personal history, family history, and clinical presentation.

Related traits and genes

CSMD3 participates in the complement regulatory family alongside CSMD1 (featured on the Complement-Mediated Brain Risk trait page) and CSMD2. All three encode extracellular scaffold proteins with CUB and sushi domains that regulate C1q and C4-mediated synaptic tagging. CSMD3 is the largest of the three and has the broadest cross-diagnostic GWAS footprint.

PCSK5 connects this trait to the neurotrophic system. BDNF, the primary substrate for PCSK5 in the psychiatric context, is also relevant to traits covering depression risk, anxiety processing, and learning and memory consolidation within the Brain and Mental Health category.

PECAM1 links this trait to the broader neuroinflammation and immune-brain interaction cluster. Immune and autoimmune traits that modulate peripheral cytokine levels — including those covering C-reactive protein, interleukin signaling, and autoimmune predisposition — share mechanistic relevance through the blood-brain barrier pathway.

Related sibling traits within Brain and Mental Health include Depression Risk (overlapping MDD liability architecture), Rapidly Progressive Alzheimer's Risk (shared neuroinflammatory and complement components), and traits covering stress response and cognitive resilience. Cross-category links include Cardiovascular Inflammation markers (relevant via the PECAM1 / endothelial junction mechanism) and Immune Activation traits (relevant via the neuroinflammatory BBB pathway).

References: Blokland GAM et al. (2022). Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry. PMID 34099189.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.